Type 2 Diabetes: Clinical Guidelines Concur on CV Risk Management

September 18, 2020
Grace Halsey

What do clinical guidelines from diabetes, cardiology, and endocrinology associations have in common? A case study quiz with an evidence-based answer explains.

Clinical treatment guidelines from leading professional societies in diabetes, cardiology, and endocrinology in the US and Europe now recommend use of 2 classes of antihyperglycemic medications for patients with type 2 diabetes (T2D) and existing atherosclerotic cardiovascular diseae (ASCVD), heart failure, chronic kidney disease, or who are at high risk for ASCVD.

Agents from the classes of glucagon-like peptide-1 receptor agonists (GLP-1 RA) and the sodium-glucose cotransporter 2 (SGLT2) inhibitors are recommended for with or at risk for cardiac and renal disease regardless of glycemic status.

In the following slides, meet a patient with T2D and comorbidities who requires treatment intensification. How would you change his current regimen? What is the evidence for that choice? And, what do the most prominent treatment guidlines say?